Structured summary
Introduction Colonisation and infection with Carbapenem-resistant Enterobacterales (CRE) in healthcare settings poses significant risks, especially for vulnerable patients. Genomic analysis can be used to trace transmission routes, supporting antimicrobial stewardship and informing infection control strategies. Here we used genomic analysis to track the movement and transmission of CREs within clinical and environmental samples.
Methods 25 isolates were cultured from clinical patient samples or swabs, that tested positive for OXA-48-like variants using the NG-Test® CARBA-5 test and whole genome sequenced (WGS) using Oxford Nanopore Technologies (ONT). 158 swabs and 52 wastewater samples were collected from the ward environment. 60 isolates (matching clinical isolate genera; Klebsiella, Enterobacter, Citrobacter and Escherichia) were isolated from the environmental samples. Metagenomic sequencing was undertaken on 36 environmental wastewater and swab samples.
Results 21/25 (84%) clinical isolates had >1 blaOXA gene and 19/25 (76%) harboured >1 blaNDM gene. Enterobacterales were most commonly isolated from environmental wastewater samples 27/52 (51.9%), then stick swabs 5/43 (11.6%) and sponge swabs 5/115 (4.3%). 11/60 (18%) environmental isolates harboured at >1 blaOXA gene and 1.9% (1/60) harboured blaNDM-1. blaOXA genes were found in 2/36 (5.5%) metagenomic environmental samples.
Discussion Potential for putative patient-patient and patient-ward transmission was shown. ONT sequencing can expedite clinical decisions whilst awaiting reference laboratory results, providing economic and patient care benefits. Metagenomic sampling needs optimization to improve sensitivity.
1 Introduction
Colonisation and subsequent healthcare associated infection (HCAI) with multi-drug resistant organisms (MDROs) is a concern for vulnerable patient groups, such as the elderly, or immunocompromised, within the hospital setting. Many of these HCAI incidents could be preventable with enhanced infection and control (IPC) measures [1]. The last line therapy for use against MDROs are the carbapenems and infection with carbapenem-resistant Enterobacterales (CRE) organisms are associated with high patient mortality rates [2]. CREs are difficult to treat as carbapenemase enzymes can hydrolyse almost all β-lactam antibiotics[3].
Oxacillinase-48-type carbapenemases (OXA-48) and New Delhi metallo-β-lactamase (NDM) are common CRE resistance mechanisms, which are now found globally, are highly mobile and no longer confined to the original bacterial species that they were characterised from [2], [4]. CRE resistance is most often transferred between bacterial isolates on mobile genetic elements, including plasmids, and a wide range of plasmid types have been seen in CRE organisms [4]. CREs are often associated with other genes that confer β-lactam resistances, such as blaSHV and blaCTX, as they can be found on the same plasmids, complicating detection [5].
CREs have been found in both community settings and hospital environments around the globe [6]. Whilst colonised patients do not need antibiotic therapy, they still pose a transmission risk, and so both colonisation and infection must be considered when undertaking IPC. CREs have been isolated from high-touch surfaces, such as door handles, medical equipment trollies, as well as bed sheets and rails, and also from hospital wastewater, including sink U-bends [2], [7], [8], [9], [10]. The colonisation of hospital wastewater by CREs and other MDROs may be particularly problematic, as this water will pass out of the hospital and into the general wastewater system. Without adequate processing at wastewater treatment plants, and the risk of sewage being released into water systems, this may lead to the distribution of these MDROs and their AMR genes back into environmental and community settings [11], [12]. This is especially likely to be problematic in low- and middle-income settings, where the treatment of wastewater may not be adequate to remove these organisms [13].
Surveillance is crucial for the containment of pathogen and AMR outbreaks, especially in hospital settings with vulnerable patients and multiple-occupancy bed bays [14]. The current standard testing for CREs is culture and phenotypic antibiotic sensitivity testing (AST), and molecular methods such as PCR or rapid diagnostic tests (RDTs), such as lateral flow devices (including the NG-Test CARBA 5) [15].
As the COVID-19 pandemic showed with real-time tracking of variants, genomic analysis provides vital enhanced surveillance of transmission patterns [16]. Phenotypic and other molecular tests for resistance genes cannot identify the genetic relatedness of isolates, and thus cannot accurately track potential transmission. The use of whole genome sequencing (WGS) and metagenomics in the diagnosis and surveillance of MDROs can identify phylogeny, novel drug resistance mutations and inform design of targeted diagnostics [17].
blaOXA- and blaNDM-mediated CRE colonisations and infections were detected in several patients occupying single-bed rooms and multiple-occupancy bed bays on wards at a North London tertiary referral hospital between 2022-2023. Temporal and spatial associations between patients indicated the possibility of ongoing transmission events but routine phenotypic and molecular testing was unable to pinpoint transmission routes. In this study we aimed to use genomic analysis to build a picture of the movement and transmission of CRE species, AMR and plasmids within clinical pathogens and environmental species found in the ward environment.
2 Methods
2.1 Sample collection
Environmental sampling was requested by the hospital Trust and IPC lead for investigation as part of the extended standard of care. Further characterisation by molecular typing of the CREs that were part of the outbreak was included as an extension of the routine standard of diagnostic care pathway. Patient metadata was obtained through the electronic clinical infection database (elCID). AST profiles of the clinical bacterial pathogens isolated relevant to the CRE surveillance cases were undertaken following the EUCAST Clinical breakpoints (v12.0) for Gram Negative bacteria [18].
Twenty-eight clinical isolates were obtained from 20 patients with a positive NG-Test® CARBA-5 (NG Biotech Laboratories) immunochromatographic lateral flow test for blaOXA and/or blaNDM resistance on multiple wards between 7 February 2022 and 20 January 2023 [19]. Four were from infection sites and 24 were CRE screen samples. These CRE screens were rectal swabs, which were plated onto speciation agar, any suspected to be CREs were tested using the CARBA-5 lateral flow test, as per Health Services Laboratories ‘healthcare associated infection detection of carbapenemase producing organisms by culture’ standard operating procedure. Phenotypic pathogen species data collected from patient samples was obtained using the MALDI-TOF (Bruker). MALDI-TOF-MS of bacterial isolates was undertaken from pure isolates no older than 24hrs from culture. Isolates were spotted in duplicate and identifications with corresponding Log scores ≥2.0 “high-confidence to the species level” were considered only, and reported in the results. Patient spatio-temporal metadata was collected, for details please contact the authors.
For environmental sampling, a site visit to ward 7D was undertaken prior to collection, to evaluate ward layout and staff and patient routes of travels and sampling locations. Samples were taken from every multiple-occupancy bed bay and single-bed room, covering affected patient areas and non-affected areas. From each bay and room every sink and drain was sampled (in both bed and bathroom areas) and shower drains sampled. Non-clinical rooms were also covered, such as the shared use pantry, staff toilets, nurses station, storage rooms, sluice and workstations on wheels.
Two hundred µL of wastewater samples were collected into sterile sample containers pre-dosed with 1mL of a neutralising buffer comprising: 3% (w/v) Tween 80, 0.3% (w/v) Lecithin, 1.0% (w/v) Sodium thiosulfate, 1.5% (w/v) K2HPO4, KH2PO4 0.05% (w/v), 1% (w/v) Poly-[sodium-4-styrenesulfonate], 0.1% (v/v) Triton® ×100 (Sigma-Aldrich, UK) and prepared in Phosphate-buffered saline (PBS) solution (Oxoid, UK) as previously described [20]. Samples were refrigerated (2-8°C) within 2 hours of collection and processed within 24 hours. Aliquots (0.5 mL, 0.1 mL) from the neat and serial 1/10 and 1/100 dilutions from the original wastewater samples were surface-plated onto selective agars: Colorex™ mSuperCARBA™ (EO Labs, UK), Brilliance CRE, E. coli Coliform, Pseudomonas CN (Oxoid, UK) and non-selective Columbia Blood Agar (Oxoid, UK). Plates were incubated aerobically at 37°C for 72 hours and inspected daily. A further 45 µL of the original samples were vacuum-filter concentrated as previously described [21] via 47mm diameter nitrocellulose membranes (0.45um pore size) and the membrane transferred to selective agars used above prior to incubation.
Cotton-tipped stick swabs (SS352, Appleton Woods) and sponge swabs (TS/15-B, Technical Service Consultants Ltd.), both pre-moistened with a neutraliser buffer were used to collect samples from difficult-to-access areas, as described above. Stick swab sampled were transferred to sterile universal tubes containing 9 mL of diluent buffer (saline), 1 mL of neutralising buffer and 3-5 glass beads. The swab contents were released by bead-washing (vortex mixing) for 30 seconds. Aliquots and serial dilutions of the resulting homogenised suspension was plated on selective and non-selective agars as above.
Suspect colonies were harvested for streak-purification onto non-selective agars and confirmed by MALDI-TOF mass spectrometry (MS) (Maldi-TOF Biotyper IVD system Bruker Daltronics). The remaining portion of the environmental samples were preserved in 500 µL 1x DNA/RNA Shield (Zymo Research Corporation).
2.2 DNA extraction and quantification
Clinical and environmental isolates were grown on Columbia horse blood plates (Oxoid Limited), then the DNA extracted using the DNeasy Blood & Tissue Miniprep Kit (Qiagen), following manufacturer’s instructions [22]. Metagenomics DNA from a subset of environmental samples, due to limited resources, was extracted directly from the environmental swab and water samples using the ZymoBIOMICS™ DNA Miniprep Kit (Zymo Research Corporation), following manufacturer’s instructions [23]. A sample of ZymoBIOMICS™ Microbial Community Standard (Zymo Research Corporation) was included, following manufacturer’s instructions [24]. DNA quality was assessed for concentration using the Qubit™ dsDNA BR Assay Kit (Thermo Fisher) and molecular weight and DNA integrity was confirmed using the Genomic DNA ScreenTape and reagents on the TapeStation 4150 (Agilent Technologies Inc.).
2.3 Library preparation
Clinical and environmental isolate DNA libraries were prepared using the Rapid Barcoding Kit 96 (SQK-RBK110.96) with a DNA input of between 50-200 ng, following manufacturer’s instructions [25]. For the environmental swab samples, metagenomic DNA libraries were prepared using the ONT Rapid PCR Barcoding Kit (SQK-RPB004) with a DNA input of 1-5 ng and following the manufacturers’ instructions [26]. ZymoBIOMICS™ Microbial Community DNA Standards (Zymo Research Corporation) were included, following manufacturer’s instructions [27].
2.4 Sequencing and basecalling
Up to 24 barcoded clinical and environmental isolate samples, or 12 barcoded environmental metagenomic samples were run together on a flow cell version R9.4.1 (Oxford Nanopore Technologies) using a MinION device for 72 hours, using the default parameters on the MinKNOW software (v23.04.6). Basecalling was performed either by the MinKNOW software alongside sequencing or using the Guppy basecalling software (v6.5.7) [41], using the flip-flop high accuracy algorithm, with a minimum Q score of 8 and minimum depth of 40x.
2.5 Data analysis
Fastq files were quality checked (QC) using FastQC (v0.21.1) and MultiQC (v1.15) and those with a read depth of >40x were included in further analysis [28], [29]. 25 clinical isolates, 60 environmental isolates, 36 metagenomics environmental samples were included in this analysis. Barcodes were trimmed from the reads using Guppy. All clinical and environmental isolate, and environmental metagenomic samples were analysed for the presence of AMR genes using KmerResistance 2.2 [30], [31] and for species using KmerFinder 3.2 (v3.0.2) [30], [32], [33]. Plasmids were identified using PlasmidFinder 2.1 (v2.0.1) [30], [34].
Clinical and environmental isolate fastq files were aligned to the reference genome for their species (C. freundii: GCF_003812345.1, C. portucalensis: GCA_023374935.1, C. youngae: GCF_015139575.1, E. cloacae: GCF_905331265.2, E. bugandensis: GCF_020042625.1, E. hormaechei: GCF_024218835.1, E. coli: GCF_000005845.2, K. pneumoniae: GCF_000240185.1, K. michigenensis: GCF_015139575.1) using MiniMap2 (v2.26) [35], then sorted and indexed using Samtools (v1.17) [36]. Alignments were visualised using Artemis (v18.1.0) [37]. Depth and coverage were calculated using Samtools. Consensus fasta files were created using Samtools and then dendograms for each species (with three or more isolates) were created using Parsnp (utilising maximal unique matches) (v1.7.4) [38], [39], [40], [41] and visualised using iTOL (v6) [42].
Speciation for the results and discussion were as per the genomic speciation. Sequence data were deposited under BioProject PRJEB76684 on the European Nucleotide Archive and outlined in supplementary materials S1, S2 and S3.
3 Results
3.1 MALDI-TOF vs WGS for isolate speciation
All 25 clinical and 48 environmental isolates were subjected to both MALDI and WGS analysis. Non-concordant C. freundii by MALDI-TOF were speciated as C. portucalensis (one clinical isolate and one environmental isolate) or C. youngae (three environmental isolates) in WGS. One MALDI-TOF call of C. braakii/freundii was called as C. youngae using WGS. One environmental isolate that MALDI-TOF identified as C. freundii was speciated as P. mirabilis (possibly a mixed culture). Non-matching E. cloacae were speciated as E. asburiae (one environmental isolate) and E. hormaechei (nine, including all five of the clinical isolates and four environmental isolates). All MALDI-TOF and WGS speciation for E. coli and K. pneumoniae was concordant. All the MALDI-TOF-called K. oxytoca were speciated as either K. michigenensis (4/5 isolates) or K. grimontii (1/5 isolates) using WGS. See Table 1 and supplementary materials S2.
3.2 Environmental sampling
210 environmental samples were collected, including 43 stick swabs, 115 sponge swabs and 52 wastewater samples. In total, 195 bacteria were isolated from 36 (16.9%) environmental samples, 76 isolates were Enterobacterales: 6 from stick swabs, 5 from sponge swabs and 65 from non-potable water samples. There was a significant difference in the proportion of samples from which Enterobacterales species were isolated from when the Chi-square test was applied p=<0.0001. Enterobacterales were isolated from 51.9% of water samples, compared with 11.6% of stick swabs and 4.3% of sponge swabs (see Table 2).
Enterobacterales were isolated from 36 different environmental samples (mean = 2.2 isolates per site, SD = 1.4). See Table 3. Table 4Table 5 details the sample sites from which each species was isolated, Table 5 describes the ward areas in which they were isolated. For full data see supplementary materials S3.
Table 6 details the environmental sample swab types, total number of bacterial species, and the total number of reads obtained from each of the 36 metagenomic sequencing sample sites that Enterobacterales were also present. There was no significant difference in the number of sequencing reads obtained, when comparing the swab type, or when comparing the swab location type. When comparing rooms, there was no significant differences, apart from Bay (beds 1-4) and bed 20 (p=0.0321). All tests were undertaken using One Way ANOVA and Tukey’s multiple comparison test. Speciation was based on genomic data, so only those that passed QC are included in the analysis.
3.3 AMR genes
3.3.1 Clinical isolates
Of the clinical isolates, blaOXA-48 was identified in 2 of the total 28 (7.1%) isolates (one C. portucalensis and one K. pneumoniae). blaNDM-1 was identified in nine (32.1%) clinical isolates (one C. portucalensis, five E. hormaechei, one E. coli and two K. pneumoniae). blaOXA genes on the CARBA-5 panel were found in 84% of clinical isolates and blaNDM genes on the CARBA-5 panel were found in 76% of clinical isolates, see Table 7. See supplementary materials S4 for full list of genes found.
3.3.2 Environmental isolates
Of the environmental isolates, blaOXA-48 was identified in 11 of the total 60 (18%) isolates (See Table 88). blaNDM-1 was identified in one (1.7%) environmental isolate, a K. michigenensis. See supplementary materials S5 for full list of genes found.
3.3.3 Metagenomic environmental samples
blaOXA-48 was identified in 1/36 (2.8%) metagenomic environmental sample, and three other blaOXA genes on the CARBA5 panel (blaOXA-204, blaOXA-370 and blaOXA-515) were found together in 1/36 (2.8%) other metagenomic environmental sample. No blaNDM genes were identified in any of the 36 metagenomic environmental samples.
3.4 Plasmids
3.4.1 Clinical isolates
The clinical isolates had a mean number of 5.6 plasmids (SD = 2.3) and a total of 20 different plasmids were identified. Table 9 describes the plasmid types and species they were found in. Col440II was the only plasmid found across all clinical isolate species. IncFIB(AP001918) was the most commonly identified plasmid.
3.4.2 Environmental isolates
The environmental isolates had a mean number of 4.3 plasmids (SD = 2.3) and a total of 42 different plasmids were identified. Supplementary materials S6 describes the plasmids and species they were found in. Col(IRGK) was the most commonly identified plasmid in 35/60 (59.3%) isolates, no plasmid was ubiquitous across all environmental isolate species.
3.4.3 Metagenomic environmental samples
Plasmids for Enterobacterales were found in 24/36 (66.6%) environmental metagenomic samples (see Supplementary materials S7). The mean number of plasmids was 3.1 (SD = 3.6).
3.5 Metagenomic species
When species were analysed in the metagenomic samples, reads mapping to the Enterobacterales order were found in 64%-75% of sites (see Table 10). When analysed, there was no significant difference in the number of reads that mapped to Citrobacter, Enterobacter, Escherichia or Klebsiella genera, using One Way ANOVA and Tukey’s multiple comparison test.
3.6 Transmission and patient metadata
One large cluster of C. freundii isolates that mapped to strain N16-03880 were all from the same room (beds 29-32) but came from both the bay HWB DWT as well as the bathroom HWB DWT samples, suggesting cross-contamination of the two sinks (see Figure 1A, C. freundii cluster #1). These, along with a toilet bowl swab from beds 15-18 were the only C. freundii found to harbour blaOXA-48 genes (see Figure 1A). All of the C. youngae environmental isolates mapped to strain CF10 (see Figure 1B, C. youngae cluster #1). The C. portucalensis isolates all mapped to different strains. The clinical isolate (patient Z1) mapped mainly (85% query coverage) to strain PNUCL1, and the environmental isolates mapped to FDAARGOS_617 and SWHIN_111. All harboured blaOXA genes, and the patient isolate additionally harboured blaNDM genes (see Figure 1C).
The E. asburiae environmental isolates all mapped to different strains: A2563, 2497 and RHBSTW-00542 (see Figure 1D). The E. cloacae environmental isolates all mapped to strain GGT036. Neither species were found to harbour any blaOXA or blaNDM genes (see Figure 1E). All of the E. hormaechei clinical isolates mapped to strain SH19PTE2 and were found to harbour blaNDM genes, whereas the environmental isolates each mapped to a different strain: Y323, F2, AR_0365 and RHBSTW-00086, none of which harboured either blaOXA or blaNDM genes (see Figure 1F).
Except patient Z2, all patient E. coli isolates mapped most closely to strain 035152. The 035152 isolates had a similar AMR profile, with all (9/9) harbouring blaOXA-181 and 7/9 harbouring blaOXA-484. Patient Z2, which mapped most closely to E. coli VREC0864, clustered with EI106, an environmental isolate from a water sample from the pantry sink’s drain waste trap, which also mapped most closely to VREC0864 (see Figure 1G, E. coli cluster #1).
The environmental isolates that mapped to K. michigenensis mapped most closely to strains RHB20-CO2, K518 and RHBSTW-00409 (two isolates from the same HWB DWT in beds 15-18). Only one was found to harbour blaOXA and blaNDM genes (see Figure 1H). Except Z5 (strain RHBSTW-00113), all of the K. pneumoniae clinical isolates mapped most closely to strain B5617 (see Figure 1I, K. pneumoniae cluster #2). Patient isolates Z3, Z4, Z5, Z6, Z17, Z18 and Z19 (all strain B5617) showed a similar AMR profile, all harbouring blaOXA-181, blaOXA-232 and blaOXA-484, and blaNDM-5. There was a cluster of environmental isolates that mapped most closely to K. pneumoniae strain 3987, all isolated from hand wash basin drain waste traps, but in differing patient bed areas around the ward (see Figure 1I, K. pneumoniae cluster #1).
9/20 (45%) patients were housed on ward 7D during their time as an inpatient and 9/9 (100%) patients had stayed in bay (beds 15-18), bay (beds 29-32) or in one of the single-occupancy bed rooms, each of which were noted to have had higher numbers of Enterobacterales isolated from the environmental samples. 4/9 (44%) of these patients had been housed in more than one of the bays, one patient had been on both bay (beds 15-18), bay (beds 29-32) and bay 19.
4 Discussion
There was evidence for the potential for patient-patient transmission for E. hormaechei, E. coli and K. pneumoniae. This conclusion is supported by the patient spatio-temporal data collected. This study also identified environment-patient transmission. The E. coli isolate from patient Z2 clustered with EI106, an environmental isolate from a wastewater sample taken from the communal pantry sink’s DWT, although they did not share the same plasmids. Whilst the clinical isolate was found to harbour the blaNDM-1 gene, no blaOXA or blaNDM genes were found in the environmental isolate. This may have been a loss or gain of function; bacteria found within the environment are less likely to encounter antibiotics or their residues compared with those in a hospitalised patient, that isolate may have lost the plasmid containing these resistance genes, conversely, they may gain plasmids from commensal organisms within the host [43].
It was noted that Enterobacterales were commonly isolated from environmental samples in bay (beds 15-18), bay (beds 29-32) and the single-occupancy bays. All the patients in this study located on ward 7D had been housed in at least one of these bays and 44% had been housed in more than one of these bays, suggesting potential host-related reservoirs. One report suggests that patients are on average 73% more likely to acquire a HAI if the patient previously occupying their room was colonised or infected, [44]. This suggests enhanced location-specific IPC would be beneficial when colonised or infected patients have been identified, and that isolation of these patients may not be enough. Enterobacterales were also isolated from environmental samples in non-clinical areas such as the shared-use pantry and the staff office. Studies have shown that HCWs can be colonised when handling patients and infected materials, it’s also possible that colonised patients or HCWs may have caused reservoirs in the pantry due to transmission of organisms via the faecal-oral route [45].
Even with comprehensive patient metadata, such as bed movements, it can be difficult to confidently infer transmission of a clonal isolate. Environmental isolates are especially complex, as the bacteria may have been present for long periods, for example by forming hard to remove biofilms in U-bends, which is in itself difficult to monitor and identify provenance [46]. For human pathogens, the ward environment may not be optimal for growth, so their doubling time may be slower. Genetic-relatedness cutoffs to determine phylogeny tend to be calculated depending on the sample number, type and environments, as well as the species, as some have faster molecular clocks than others. These data are often missing for isolates extracted from the environment. [47].
Whilst all clinical isolates tested positive for OXA-48-like variants using the CARBA-5 test, only 84% of the clinical isolates were found to harbour blaOXA genes that the CARBA-5 panel tested for. Studies have shown the specificity of the CARBA-5 test to vary from 96% (from blood cultures) to 100% from isolates and rectal swabs [48], [49], [50], [51]. The clinical sites that the swabs were taken from in this study varied and the majority came from CRE screens, usually rectal, rather than sites of infection. It is possible that the CARBA-5 panel picked up blaOXA genes from other colonising species present in CRE screening samples, as these were not sterile sites. Most of the clinical and environmental isolates found to harbour the blaOXA-48 gene also had other blaOXA genes present, as well as other resistance genes, such as blaCTX and blaSHV. These are often found together on the same plasmids and are likely to be transferred between bacteria collectively [4]. Indeed, all of the C. portucalensis isolates identified in this study were found to harbour blaOXA genes, with the clinical isolate also containing blaNDM-1.
Whilst Col440II, which does not carry resistance or virulence genes, was the only plasmid found across all clinical isolate species. IncFIB(AP001918), the most commonly identified plasmid, is linked with resistance to several antimicrobial classes, including β-lactams, aminoglycosides, sulfonamides and tetracyclines, but was less commonly identified in environmental isolates [52], [53]. The prevalence of IncFIB(AP001918) in clinical samples suggests that genomic analysis of plasmids as well as isolates is important for enhanced IPC surveillance.
In this study, the initial MALDI-TOF speciation for C. freundii, E. cloacae and K. oxytoca isolates did not all match with the WGS speciation. Both methods were more consistent when comparing environmental rather than clinical isolates. All three species complexes contain multiple, closely related species, which can make it difficult to fully resolve using conventional methods. C. portucalensis is a relatively newly described clinical pathogen but has the capacity to harbour and transmit AMR genes, thus identifying it to species level may be important in the future [54].
The use of genomic analysis in enhanced outbreak surveillance technologies provides greater detail on the potential transmission of MDROs and their associations with patients, HCWs and the ward Environment. Platforms such as ONT shows promise, especially for use in low- and middle-income countries, as long read sequencing enables read lengths of thousands, rather than hundreds, of base pairs which is especially useful when resolving speciation in metagenomic samples.
5 Conclusions
Understanding the resistance genes, plasmids and sequencing types present in an environment can provide greater resolution than phenotypic and other molecular methods, helping to identify targeted IPC interventions in outbreak situations. As a result of the evidence from this study highlighting the presence of CREs in wastewater, the hospital estates team has since replaced all of the sink U-bends on the sampled ward, as well as reviewed and revised ward IPC practices to reduce potential transmission risks. Due to the number of colonised patients found, this study also recommends the use of more widespread CRE screening for hospitalised patients, to enable interventions to reduce the risks from human and environmental reservoirs and therefore reduce risks to vulnerable patients.
Overview:
Putative patient-patient and patient-ward transmission was identified, utilising WGS and patient metadata
CREs were more commonly isolated from wastewater samples than either stick swabs or sponge swabs
All patients in this study tested positive for OXA-48-like carbapenemase variants using the NG-Test® CARBA-5 rapid diagnostic test, 84% of patient isolates harboured a blaOXA gene present on the CARBA-5 panel
blaOXA and blaNDM genes were identified in fewer environmental CRE isolates, compared with clinical isolates, suggesting either different populations, or a loss/gain of plasmids or genes
Conflicts of interest
The authors declare no conflicts of interest.
Funding
This research was funded by the Royal Free London NHS Foundation Trust.
Ethical approval
This diagnostic service evaluation was undertaken at the request of the Division of Nursing in support of the Infection Prevention and Control team as part of enhanced standard of care practices for IPC outbreak investigation. This project is under HRA approval for ELCID and registered with Health Services London. IRAS project ID: 283831, National HRA REC reference: 20/HRA/4928, Local REC: RFL R&D ref: 134895, HSL Project number: 1529
Data sharing
All genomic data produced in the present work are contained in the manuscript or available online under ENA bioproject number PRJEB76684. For patient and ward metadata, please contact the authors.
Data Availability
All data produced in the present work are contained in the manuscript or available online under ENA bioproject number PRJEB76684. For patient and ward metadata, please contact the authors.
Abbreviations
- AMR
- Antimicrobial resistance
- AST
- Antibiotic sensitivity test
- CRE
- Carbapenem-resistant Enterobacterales
- DWT
- Drain waste trap
- HCAI
- Healthcare associated infection
- HWB
- Hand wash basin
- IPC
- Infection prevention and control
- MDRO
- Multi-drug resistant organism
- NDM
- New Delhi metallo-beta lactamase
- ONT
- Oxford Nanopore Technologies
- RDT
- Rapid diagnostic test
- SD
- Standard deviation
- WoW
- Workstation on wheels
References
- [1].↵
- [2].↵
- [3].↵
- [4].↵
- [5].↵
- [6].↵
- [7].↵
- [8].↵
- [9].↵
- [10].↵
- [11].↵
- [12].↵
- [13].↵
- [14].↵
- [15].↵
- [16].↵
- [17].↵
- [18].↵
- [19].↵
- [20].↵
- [21].↵
- [22].↵
- [23].↵
- [24].↵
- [25].↵
- [26].↵
- [27].↵
- [28].↵
- [29].↵
- [30].↵
- [31].↵
- [32].↵
- [33].↵
- [34].↵
- [35].↵
- [36].↵
- [37].↵
- [38].↵
- [39].↵
- [40].↵
- [41].↵
- [42].↵
- [43].↵
- [44].↵
- [45].↵
- [46].↵
- [47].↵
- [48].↵
- [49].↵
- [50].↵
- [51].↵
- [52].↵
- [53].↵
- [54].↵